Trailing Twelve Months Revenue Growth: Kronos Bio Corporation (KRON)

Public company logo of kronosbio.com (KRON)

Kronos Bio, Inc. (KRON) develops targeted therapies against tumor factors, relying on reimbursements from insurance systems and medical centers. Year-over-year sales growth (TTM) illustrates the impact of patent protection and FDA approvals, where the value 0.00 describes the current level. The company is currently expanding its precision medicine portfolio, researching complex oncogenic pathways to combat hard-to-treat forms of cancer.

Kronos Bio, Inc. (KRON): Revenue Growth YoY (Last 12 Months) from 02/11/2024 to 02/20/2024

Kronos Bio, Inc. - analytical breakdowns and key metrics (KRON)

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Summary company analytics:Kronos Bio Corp
Brand item of Kronos Bio Corporation

Kronos Bio, Inc. (KRON) maintains a strong academic position within the oncology sector, although its capital management efficiency requires strict monitoring. By analyzing the historical year-over-year revenue growth trend over the last 12 months, an investor can filter out market noise and determine whether growth is driven by real business expansion or merely inflationary factors, which is critical for assessing the company's cash burn rate.

Who Kronos Bio, Inc. competes with

Incyte Pharma - Sales Growth YoY (Last Twelve Months)|HUTCHMED Corp - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Nuvation Bio Inc.|DAWN: Sales Growth YoY (TTM)|Revenue Growth Rate YoY (Last Twelve Months) Monopar Pharma MNPR|Revenue Growth YoY (Last 12 Months) INBX|Trailing Twelve Months Revenue Growth I-Mab Biopharma IMAB|Revenue Growth YoY (Last 12 Months) FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Revenue Dynamics YoY (Last Twelve Months)|Nuvectis Pharma, Inc. - Revenue Growth YoY (Last 12 Months)|Revenue Change YoY (Last 12 Months) CHRS (Coherus BioSciences)|Corbus Pharma - Sales Growth YoY (TTM)|Revenue Dynamics YoY (Last Twelve Months) CRDF (cardiffoncology.com)|BYSI: Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth BioAtla Corp (BCAB)|Sales Growth YoY (Last Twelve Months) Lixte Biotechnology Holdings, Inc.|CTXR: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (TTM) CLRB|Sales Growth YoY (TTM) BioLineRx Corporation (BLRX)|Sales Growth YoY (Last Twelve Months) Can-Fite BioPharma, Ltd. CANF|APRE (aprea.com) - Trailing Twelve Months Sales Growth|KZIA: Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth Silexion Therapeutics|NuCana plc (NCNA) - Sales Growth YoY (Last Twelve Months)|Revenue Growth YoY (Last 12 Months) Chimerix, Inc|Revenue Growth YoY (Last 12 Months) CYCC|Revenue Growth YoY (Last 12 Months) G1 Therapeutics (GTHX)|Sales Growth YoY (Last Twelve Months) Kintara (KTRA)|Revenue Growth YoY (Last 12 Months) Oncternal ONCT|Portage Biotech - Revenue Growth YoY (Last 12 Months)